Hemodynamic effects of chronic tetrandrine treatment in Sprague-Dawley rats

Chinese Journal of Physiology

Volumn 40, Issue 3, 1997, Pages 175-178

  Huang, Yi Tsau ^a   Cheng, Yuh Ren ^a   Lin, Han Chieh ^a,b   Chen, Chieh Fu ^c   Hong, Chuang Ye ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

Author keywords

Calcium channel antagonist; Radioactive microsphere method; Tetrandrine

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; RADIOACTIVE MICROSPHERE; TETRANDRINE;

ANTIHYPERTENSIVE THERAPY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART INDEX; HEMODYNAMICS; INTRAGASTRIC DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; SYSTEMIC VASCULAR RESISTANCE;

EID: 0030753204     PISSN: 03044920     EISSN: 26660059     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. + channels. Life Sci. 56: 295-306, 1995.
2. ++ antagonist: effects and mechanisms of action in vascular smooth muscle cells. J. Pharmacol. Exp. Ther. 273: 32-39, 1995.
3. Qian, J.Q., M.J.M.C. Thoolen, J.C.A. van Meel, P.B.M.W.M. Timmermans, and P.A. van Zwieten. Hypotensive activity of tetrandrine in rats: investigation into its mode of action. Pharmacology 26: 187-197, 1983.
4. Xu, Y., and M.-R. Rao. Effects of tetrandrine on left ventricle hypertrophy in deoxycorticosterone acetate-salt hypertensive rats. Eur. J. Pharmacol. 278: 1-7, 1995.
5. Liu, T.-B., H.-C. Lin, Y.-T. Huang, C.-M. Sun, and C.-Y. Hong. Portal hypotensive effects of tetrandrine and verapmil on portal hypertensive rats. J. Pharm. Pharmacol. 49: 85-8, 1997.
6. Huang, Y.T., T.B. Liu, Y.R. Cheng, H.C. Lin, C.F. Chen, and S.M. Chen. Chronic portal hypotensive effects of tetrandrine and verapamil on portal hypertensive rats. Asia Pac. J. Pharmacol. 1997, in press.
7. Lin, H.-C., M.C.-M. Yang, M.-C. Hou, S.-M. Li, Y.-T. Huang, P.-C. Yu, Y.-T. Tsai, and S.-D. Lee. Effects of long-term administration of octreotide in portal vein-stenosed rats. Hepatology 23: 537-543, 1996.
8. Doyle, A.E. Calcium antagonists. In: Handbook of Hypertension, Vol. 11, Clinical Pharmacology of Antihypertensive Drugs, edited by A.E. Doyle. Amsterdam, The Netherlands: Elsevier Science Publishers B.V., pp. 424-448, 1988.
9. Opie, L.H. Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. Prog. Cardiovasc. Dis. 38: 273-290, 1996.
10. Huang, Y.-T., Y.-R. Cheng, H.-C. Lin, C.-F. Chen, and C.-Y. Hong. Haemodynamic effects of chronic tetrandrine treatment in portal hypertensive rats. J. Gastroenterol. Hepatol. 1997, in press.
11. Zeng, F.-D., D.H. Shaw Jr, and R.I. Ogilvie. Kinetic disposition and hemodynamic effects of tetrandrine in anesthetized dogs. J. Cardiovasc. Pharmacol. 7: 1034-1039, 1985.
12. Fang, D.-C., W.-X. Yao, Q.U. Ling, and M.-X. Jiang. Effects of tetrandrine on cat papillary muscle. Acta Pharmacol. Sin. 2: 163-166, 1981.
13. Lieberman, I., D.P. Lentz, G.A. Trucco, W.K. Seow, and Y.H. Thong. Prevention by tetrandrine of spontaneous development of diabetes mellitus in BB rats. Diabetes 41: 616-619, 1992.